Scientific Evidence
Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations
Oct 2020
Define changes in clinical management resulting from the use of the prognostic 31-gene expression profile (31-GEP) test for cutaneous melanoma in a surgical oncology practice.
Publication: Future Oncology
Integration of a 31-gene expression profile into clinical decision-making in the treatment of cutaneous melanoma
Aug 2020
Retrospective review and early experience in utilizing 31-GEP in intermediate melanomas and its effect on clinical management.
Publication: The American Surgeon
Clinical validity of a gene expression signature in diagnostically uncertain neoplasms
Jun 2020
A retrospective study demonstrating high diagnostic accuracy of the 23-GEP in diagnostically uncertain cases when evaluated against clinical outcomes.
Publication: Personalized Medicine
A systematic review and meta-analysis of gene expression profiling for primary cutaneous melanoma prognosis
May 2020
Systematic review of available evidence on GEP for prognosis. Included meta-analysis of 6 studies on the 31-GEP. Clinical implications show that 31-GEP can better assess prognosis leading to more appropriate patient management.
Publication: SKIN: Journal of Cutaneous Melanoma
Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients
Mar 2020
Meta-analysis stage I-II patients. GEP consistently identifies melanoma patients at increased risk of metastasis, independent of clinicopathologic features and can be used in conjunction with traditional staging to improve patient risk stratification.
Publication: Journal of the American Academy of Dermatology
Appropriate use criteria for the integration of diagnostic and prognostic gene expression profile assays into the management of cutaneous malignant melanoma: an expert panel consensus-based modified delphi process assessment
Sep 2019
Expert panel of 9 dermatologists developed 29 clinical scenarios creating an evidence based framework for AUC recommendations for integration of melanoma GEP tests into clincial practice.
Publication: SKIN: Journal of Cutaneous Melanoma
Level of evidence review for a gene expression profile test for cutaneous melanoma
Jul 2019
Review the current literature and establish the level of evidence for a cutaneous melanoma 31-GEP test.
Publication: American Journal of Clinical Dermatology
Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma
Jul 2019
Multi center study establishing appropriate use criteria for determining risk of recurrence in patients with tumors >0.3mm in thickness.
Publication: SKIN: Journal of Cutaneous Melanoma
Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma
Apr 2019
Independent, prospective study with over 3.5 years of follow-up, showing results consistent with previous validation studies with GEP class score as statistically associated with MSS, DMFS and RFS.
Publication: Cancer Medicine
Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions
Apr 2019
Clinical validation study of the 23-GEP in lesions with clinical outcomes and follow-up data.
Publication: Human Pathology
Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients
Jan 2019
A prospective multicentre cohort study. Multicentre evaluation the early prognostic performance of a genetic signature in a multicentre prospectively evaluated cohort.
Publication: Journal of the European Academy of Dermatology and Venereology
Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck
Jan 2019
Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method and both were independent predictors of recurrence in multivariate analysis.
Publication: Head and Neck